Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(.omega.-phenyl-.omega.-hydroxyalkyl)imidazoles
摘要:
A novel series of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles was synthesized and evaluated for anticonvulsant activity in mice against maximal electroshock induced seizures. Some of the compounds showed an activity comparable to or better than phenytoin and phenobarbital. The N-[beta-[4-(beta-phenylethyl)phenyl]-beta-hydroxyethyl]imidazole (38) was selected for further studies; preclinical toxicology and additional efficacy evaluations are in progress. Structure-activity relationships are discussed.
Imidazolium salts, intermediates thereto and their use
申请人:SCHERING AKTIENGESELLSCHAFT
公开号:EP0131302A2
公开(公告)日:1985-01-16
The imidazolium salts described are useful as antiarrhythmic agents. A method of treating arrhythmia by increasing the refractoriness of cardiac tissue is provided as well as pharmaceutical formulations containing such imidazolium salts.
Nouveaux dérivés d'imidazole, leurs procédés de préparation et leurs propriétés antifongiques
申请人:Instituto de Investigacion
Y Desarrollo Quimico Biologico S.A.
公开号:EP0276583A1
公开(公告)日:1988-08-03
La présente invention concerne de nouveaux dérivés d'imidazole de formule :
dans laquelle R représente un atome d'halogène, ainsi que leurs sels d'addition pharmaceutiquement acceptables.
Les composés de l'invention sont utiles comme antifongiques.
本发明涉及式中 R 代表卤素原子的新咪唑衍生物及其药学上可接受的加成盐。 本发明化合物可用作抗真菌药。
Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(.omega.-phenyl-.omega.-hydroxyalkyl)imidazoles
作者:Dante Nardi、Alberto Tajana、Amedeo Leonardi、Renzo Pennini、Ferruccio Portioli、Maria Jose Magistretti、Alessandro Subissi
DOI:10.1021/jm00138a017
日期:1981.6
A novel series of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles was synthesized and evaluated for anticonvulsant activity in mice against maximal electroshock induced seizures. Some of the compounds showed an activity comparable to or better than phenytoin and phenobarbital. The N-[beta-[4-(beta-phenylethyl)phenyl]-beta-hydroxyethyl]imidazole (38) was selected for further studies; preclinical toxicology and additional efficacy evaluations are in progress. Structure-activity relationships are discussed.